ATE471945T1 - Als medikament geeignete lösliche varianten des gp130-moleküls - Google Patents

Als medikament geeignete lösliche varianten des gp130-moleküls

Info

Publication number
ATE471945T1
ATE471945T1 AT06841152T AT06841152T ATE471945T1 AT E471945 T1 ATE471945 T1 AT E471945T1 AT 06841152 T AT06841152 T AT 06841152T AT 06841152 T AT06841152 T AT 06841152T AT E471945 T1 ATE471945 T1 AT E471945T1
Authority
AT
Austria
Prior art keywords
soluble
medication
molecule used
soluble variants
polypeptide
Prior art date
Application number
AT06841152T
Other languages
German (de)
English (en)
Inventor
Dirk Seegert
Georg Waetzig
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Application granted granted Critical
Publication of ATE471945T1 publication Critical patent/ATE471945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
AT06841152T 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls ATE471945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05028420A EP1801121A1 (en) 2005-12-23 2005-12-23 Soluble gp130 molecule variants useful as a medicament
PCT/EP2006/012515 WO2007071449A1 (en) 2005-12-23 2006-12-22 Soluble gp130 molecule variants useful as a medicament

Publications (1)

Publication Number Publication Date
ATE471945T1 true ATE471945T1 (de) 2010-07-15

Family

ID=36233865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841152T ATE471945T1 (de) 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls

Country Status (9)

Country Link
US (1) US7851182B2 (enExample)
EP (2) EP1801121A1 (enExample)
JP (1) JP5390191B2 (enExample)
AT (1) ATE471945T1 (enExample)
AU (1) AU2006328909A1 (enExample)
CA (1) CA2633213A1 (enExample)
DE (1) DE602006015103D1 (enExample)
ES (1) ES2347694T3 (enExample)
WO (1) WO2007071449A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
EP2050759A1 (en) * 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
RS61947B1 (sr) 2014-12-01 2021-07-30 Ferring Bv Davanje selektivnog inhibitora il-6-trans-signalizacije
EP3227325B1 (en) 2014-12-01 2024-04-10 Ferring B.V. Selective il-6-trans-signalling inhibitor compositions
US20190002915A1 (en) * 2015-12-14 2019-01-03 The Trustees Of The University Of Pennsylvania Compositions and methods for regulatable antibody expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
AU778998B2 (en) * 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
JP2002534962A (ja) * 1999-01-07 2002-10-22 レキシジェン ファーマシューティカルズ コーポレイション Ｆｃ融合タンパク質としての抗肥満症タンパク質の発現および輸送
ES2298106T3 (es) * 2000-04-21 2008-05-16 Conaris Research Institute Ag Proteinas de fusion que comprenden dos moleculas gp130 solubles.
ATE384783T1 (de) * 2001-10-19 2008-02-15 Zymogenetics Inc Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
EP1491554A1 (en) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
CN1926237A (zh) * 2004-01-28 2007-03-07 森托尼克斯制药有限公司 用于治疗不育症的异二聚体促卵泡激素－Fc(FSH－Fc)融合蛋白

Also Published As

Publication number Publication date
CA2633213A1 (en) 2007-06-28
JP2009520480A (ja) 2009-05-28
WO2007071449A1 (en) 2007-06-28
AU2006328909A1 (en) 2007-06-28
DE602006015103D1 (de) 2010-08-05
EP1994053A1 (en) 2008-11-26
JP5390191B2 (ja) 2014-01-15
EP1801121A1 (en) 2007-06-27
EP1994053B1 (en) 2010-06-23
US20090227499A1 (en) 2009-09-10
ES2347694T3 (es) 2010-11-03
US7851182B2 (en) 2010-12-14

Similar Documents

Publication Publication Date Title
Scalise et al. The human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health
Ocaña-Guzman et al. TIM-3 regulates distinct functions in macrophages
Bai et al. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization
Liu et al. D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms
Tan et al. Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1)
Yates-Binder et al. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis
EA200801166A1 (ru) Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
Lansdell et al. Palau’amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
ATE473759T1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
DE60331329D1 (de) Kristallstruktur des aurora-2 proteins und dessen bindungstaschen
JP2012522529A5 (enExample)
CY1113096T1 (el) Αντισωματα της ip-10 και οι χρησεις αυτων
Suzuki et al. Syndecan binding sites in the laminin α1 chain G domain
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
ATE471945T1 (de) Als medikament geeignete lösliche varianten des gp130-moleküls
Voltà-Durán et al. Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering
Gironda-Martínez et al. Identification and validation of new interleukin-2 ligands using DNA-encoded libraries
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
Liu et al. The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin
Ensenberger et al. Specific interactions between F1 adhesin of Streptococcus pyogenes and N-terminal modules of fibronectin
Li et al. Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1, 12-diaziridinyl-4, 9-diazadodecane
Jouffroy et al. Development of a concise and robust route to a key fragment of MCL-1 inhibitors via stereoselective defluoroborylation
JP2008539795A5 (enExample)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties